Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642780 · ClinicalTrials.gov registry record · Phase 2
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
A Phase 2 study of Solid Tumor, sponsored by Klus Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05642780 is a Phase 2 study of Solid Tumor that is active but no longer recruiting, run by Klus Pharma. The registered enrollment target is 240 participants, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT05642780, a Phase 2 study of Solid Tumor, is active but no longer recruiting, sponsored by Klus Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG SKB264
Study Locations (20)
Other
- Flinders Medical Centre - Bedford Park
- Wollongong Hospital - Kogarah
- Algemeen Ziekenhuis Klina - Brasschaat
- Grand Hôpital de Charleroi - Site Notre-Dame - Charleroi
- Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Centre Hospitalier de l'Université de Montréal (CHUM) - Montreal
Texas
- Texas Oncology, P.A. Amarillo, TX - Amarillo
- Texas Oncology, P.A. Austin, TX - Austin
Indiana
- Community Clinical Research Center - Anderson
Kentucky
- Norton Cancer Institute - Louisville
Maryland
- Anne Arundel Medical Center (AAMC) - Annapolis
Minnesota
- UT Health East Texas - Hope Cancer Center Tyler - Tyler
New York
- Westchester Medical Center - Hawthorne
Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc. Roanoke, VA - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642780
The ClinicalTrials.gov registry entry for NCT05642780 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target. The listed sponsor is Klus Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05642780 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT05642780 about?
NCT05642780 is a clinical study titled "SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors". The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
What is the current status of trial NCT05642780?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2023-01-17. Estimated completion is 2027-12-31.
What conditions does trial NCT05642780 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05642780?
The interventions under investigation include: Pembrolizumab (DRUG), SKB264 (DRUG).
Who is sponsoring clinical trial NCT05642780?
This trial is sponsored by Klus Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642780 being conducted?
This trial has 20 study locations across Indiana, Kentucky, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.